SecBot SecBot
8-K ·Filed Apr 17, 2026

MBIO

MUSTANG BIO, INC.
BEARISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001104659-26-044890
8-K context-dependent: Items 3.01
Actionable Insight ▼ Bearish

Monitor stock price closely through October 12, 2026. A reverse stock split announcement would be a temporary reprieve but dilutive. Delisting would severely impact liquidity and likely trigger further price declines. This is a high-risk situation for a micro-cap biotech with limited options.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
MBIO ▼ -14.59% at T+60d
SHORT call ✓ call won +14.59% · α vs SPY +21.37% · entry $0.7400 → $0.6320
Entry = T+0 close
Apr 17, 2026
via day close
T+1d
-3.24%
call +3.24% · α +2.59%
$0.7160
settled 6mo ago
T+5d
+2.70%
call -2.70% · α -1.79%
$0.7600
settled 6mo ago
T+20d
-19.19%
call +19.19% · α +23.39%
$0.5980
settled 6mo ago
T+60d
-14.59%
call +14.59% · α +21.37%
$0.6320
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Mustang Bio (MBIO) received a Nasdaq delisting notice due to its stock trading below $1.00 for 30 consecutive days. The company has until October 12, 2026, to regain compliance, typically via a reverse stock split. Failure risks delisting, severely impacting liquidity for this $6M market cap biotech.

Key Facts

  • Received Nasdaq delisting notice on April 15, 2026, for failing to maintain $1.00 minimum bid price
  • Has 180-day grace period until October 12, 2026, to regain compliance
  • Compliance can be achieved by maintaining a $1.00+ closing price for 10 consecutive business days
  • May pursue a reverse stock split if needed to regain compliance
  • Market cap is only $6M, indicating extreme financial distress

Financial Impact

High risk of delisting for a $6M market cap company; potential 90%+ decline if delisted to OTC market

liquidityshare priceinstitutional ownershipmarket capitalization

Risk Factors

  • Delisting from Nasdaq to OTC market, drastically reducing liquidity and institutional ownership
  • Reverse stock split would dilute existing shareholders and signal financial distress
  • Inability to raise capital or attract investors while under delisting threat

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-044890
Document: 0001104659-26-044890-index-headers.html0001104659-26-044890
Document: 0001104659-26-044890-index.html0001104659-26-044890
Document: 0001104659-26-044890.txt0001104659-26-044890
2 reports for MBIO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MBIO — sortable, filterable
TypeNow
Oct 15, 2026
11d ago
8-K
BEARISH ★ 6/10
$0.3764 $0.3700▲ +1.70%▲ +1.27%$0.3600 (+4.36%)
Apr 17, 2026
27w ago
8-K
BEARISH ★ 8/10
$0.7400 $0.7600▼ −2.70%▼ −1.79%$0.3600 (+51.35%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 4h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026